Download Sample
Add to CartCIS Insulin Market
By Product;
Rapid-Acting Insulin, Long-Acting Insulin, Combination Insulin, Biosimilar and OthersBy Type;
Human Insulin and Insulin AnalogBy Application;
Type I Diabetes and Type II DiabetesBy Distribution;
Hospitals, Pharmacies, Retail & Specialty Pharmacies and OthersBy Geography;
North America, Europe, Asia Pacific, Middle East & Africa and Latin America - Report Timeline (2021 - 2031)CIS Insulin Market Overview
CIS Insulin Market (USD Million)
CIS Insulin Market was valued at USD 5,261.89 million in the year 2024. The size of this market is expected to increase to USD 13,996.72 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 15.0%.
CIS Insulin Market
*Market size in USD million
CAGR 15.0 %
| Study Period | 2025 - 2031 |
|---|---|
| Base Year | 2024 |
| CAGR (%) | 15.0 % |
| Market Size (2024) | USD 5,261.89 Million |
| Market Size (2031) | USD 13,996.72 Million |
| Market Concentration | Low |
| Report Pages | 302 |
Major Players
- Bristol-Myers Squibb
- Novartis
- Takeda Pharmaceuticals
- Boehringer Ingelheim
- Biocon
- Dongbao Enterprise Group Co. Ltd.
- Merck KGaA
- Oramed Pharmaceuticals Inc.
- Halozyme Therapeutics
- Wanbang Biopharma
- Xinbai Pharmaceutical
Market Concentration
Consolidated - Market dominated by 1 - 5 major players
CIS Insulin Market
Fragmented - Highly competitive market without dominant players
The CIS Insulin Market is advancing rapidly due to innovative insulin synthesis techniques and smart delivery mechanisms. With over 65% of insulin production using recombinant methods, manufacturers are ensuring consistency and efficiency. These innovations are boosting therapy effectiveness while opening fresh opportunities for improved patient care. Continued enhancements in device design and drug formulation are driving widespread adoption and trust in modern insulin therapies.
Strategic Alliances Fueling Growth
Collaborative frameworks and strategic partnerships are proving essential, as over 58% of biosimilar projects now involve joint ventures. These efforts have supported expansion into new clinical territories and are guiding growth strategies within the sector. Mergers and cooperative models are facilitating rapid access to insulin products, lowering development time, and improving regulatory compliance. The market is being shaped by a proactive approach to shared innovation.
Tech Integration Boosts Adoption
The integration of advanced insulin delivery systems, used by more than 60% of users, marks a turning point in insulin therapy. Features like automated dosing and app-based monitoring are helping users optimize their treatment routines. This reflects the market’s evolution through technological advancements, bringing greater efficiency and personalization. Digital transformation is becoming central to market expansion and future growth initiatives.
Outlook Shaped by Strategic Vision
The CIS Insulin Market holds a promising future outlook, bolstered by ongoing innovation, effective strategies, and a wave of expansion initiatives. Over 62% of insulin R&D activities now involve external collaborations, emphasizing the shift toward open, multi-stakeholder development models. With a rising demand for smarter, more accessible insulin therapies, the market is preparing to scale efficiently while ensuring long-term growth through unified strategic efforts.
CIS Insulin Market Key Takeaways
-
Rising global diabetes burden continues to elevate demand for reliable and cost-effective insulin therapies, positioning CIS insulin as an accessible treatment option in emerging and mid-tier healthcare markets.
-
Growing emphasis on affordability and price-sensitive insulin solutions is boosting usage of CIS insulin where cost barriers limit penetration of modern analog insulin products.
-
Expansion of government reimbursement programs and public diabetes initiatives in developing regions supports broader adoption and improves treatment accessibility.
-
Steady clinical preference for proven efficacy and safety profiles sustains demand among patients requiring stable glycemic control without premium pricing pressure.
-
Increasing uptake in hospital and institutional channels reflects cost-optimized procurement strategies and continuity-of-care requirements for diabetic patients.
-
Growing patient education efforts around self-administration and diabetes management encourages wider use of vial-and-syringe and pen-based CIS insulin formats.
-
Strategic collaborations between regional pharmaceutical manufacturers, public health bodies, and supply partners reinforce distribution networks and ensure consistent insulin availability.
CIS Insulin Market Recent Developments
-
In June 2024, Eli Lilly and Company (NYSE: LLY) announced results from SYNERGY-NASH, a Phase 2 clinical trial involving 190 participants evaluating tirzepatide in adults with metabolic-associated steatohepatitis (MASH) and stage 2 or 3 fibrosis, with or without type 2 diabetes. The findings highlight tirzepatide’s potential to address key unmet needs in liver disease management.
-
In May 2024, Novo Nordisk released findings from the FRONTIER 2 trial, a 26-week study involving 254 participants aged 12 and older with haemophilia A. The research evaluated Mim8 injections administered weekly or monthly, comparing their efficacy against no preventive therapy and traditional coagulation factor prophylaxis, demonstrating promising results in bleed prevention.
CIS Insulin Market Segment Analysis
In this report, the CIS Insulin Market has been segmented by Product Type, Source Type, Application, and Geography.
CIS Insulin Market, Segmentation by Product Type
The CIS Insulin Market has been segmented by Product Type into Rapid Acting Analog, Short Acting Insulin, Intermediate Acting Insulin, Long Acting Analog, and Pre-Mixed.
Rapid Acting Analog
Rapid acting analogs are widely used for controlling postprandial glucose spikes and offer quick onset of action. In the CIS region, they account for approximately 25% of the insulin market due to their growing use in intensive insulin therapy and convenience in mealtime administration. Their rising demand is driven by increasing diabetes prevalence and better glycemic control outcomes.
Short Acting Insulin
Short acting insulin remains a vital component in traditional insulin regimens, especially among elderly patients. Holding a market share of nearly 18%, it is commonly preferred in hospital settings due to its predictable action and cost-effectiveness. However, its use is gradually declining in favor of newer analogs.
Intermediate Acting Insulin
Intermediate acting insulin, primarily NPH insulin, continues to serve as a bridge between short and long acting formulations. It contributes around 15% of the market, especially in public healthcare systems and rural settings where affordability and accessibility are key. Its twice-daily dosing pattern provides flexibility for certain patient groups.
Long Acting Analog
Long acting analogs lead the market with an estimated 30% share due to their once-daily dosing and reduced risk of nocturnal hypoglycemia. These insulins are preferred for basal therapy and are a core component of modern diabetes management, especially in urban CIS populations embracing advanced treatment protocols.
Pre-Mixed
Pre-mixed insulins represent about 12% of the CIS insulin market, offering a balanced combination of basal and prandial insulin in a single injection. They are particularly popular among patients seeking simplicity and fewer injections per day, making them a favorable choice in outpatient diabetes care programs.
CIS Insulin Market, Segmentation by Source Type
The CIS Insulin Market has been segmented by Source Type into Insulin Analogs and Human Recombinant Insulin.
Insulin Analogs
Insulin analogs dominate the CIS insulin market with a share of approximately 65%, driven by their enhanced pharmacokinetics and improved patient compliance. These synthetically modified insulins offer more predictable absorption and lower risk of hypoglycemia, making them the preferred choice in modern diabetes management. Increased availability and patient awareness are accelerating their uptake across urban areas.
Human Recombinant Insulin
Human recombinant insulin holds around 35% of the market share and continues to be widely used due to its affordability and established safety profile. It is especially popular in public healthcare systems and among cost-sensitive populations. While its market share is gradually being eroded by analogs, it remains a cornerstone therapy in many CIS regions.
CIS Insulin Market, Segmentation by Application
The CIS Insulin Market has been segmented by Application into Type I & Other Diabetes, and Type II Diabetes.
Type I & Other Diabetes
Type I and other less common forms of diabetes account for nearly 30% of insulin usage in the CIS region. Patients in this segment are entirely dependent on insulin therapy from diagnosis, making it a consistent market base. The demand is driven by early diagnosis, rising incidence of autoimmune diabetes, and increasing pediatric cases requiring lifelong insulin management.
Type II Diabetes
Type II diabetes dominates the application segment with approximately 70% market share due to its growing prevalence across adult populations in the CIS. The use of insulin in this segment is typically for advanced disease stages or cases with poor glycemic control. Rising obesity rates, sedentary lifestyles, and aging demographics are fueling sustained demand in both urban and rural areas.
CIS Insulin Market, Segmentation by Geography
In this report, the CIS Insulin Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East, and Africa, and Latin America.
Regions and Countries Analyzed in this Report
CIS Insulin Market Share (%), by Geographical Region
North America
North America holds a significant share of around 32% in the CIS insulin market, driven by its advanced healthcare infrastructure, high prevalence of diabetes, and strong adoption of insulin analogs. Government initiatives, widespread insurance coverage, and continuous product innovation also contribute to market expansion in the region.
Europe
Europe accounts for nearly 27% of the market, with demand propelled by an aging diabetic population and robust public health systems. The region emphasizes early diagnosis and personalized treatment approaches, fostering the adoption of both human recombinant insulin and analogs, especially in Western European countries.
Asia Pacific
The Asia Pacific region represents approximately 22% of the CIS insulin market and is experiencing rapid growth due to a rising diabetic population, urbanization, and increasing healthcare investments. Countries like China and India are driving demand through government-led diabetes awareness programs and improved access to affordable insulin therapies.
Middle East and Africa
Middle East and Africa contribute close to 10% of the market, with growth supported by rising diabetes incidence, healthcare infrastructure development, and increased availability of low-cost insulin options. However, access challenges and affordability issues continue to limit broader adoption in some regions.
Latin America
Latin America holds around 9% of the CIS insulin market share, driven by growing rates of type II diabetes and government efforts to improve diabetes care accessibility. Public health initiatives and expanding pharmaceutical distribution networks are enhancing insulin availability across both urban and rural settings.
CIS Insulin Market Forces
This report provides an in depth analysis of various factors that impact the dynamics of Global CIS Insulin Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Drivers, Restraints and Opportunity Analysis
This matrix outlines how core market forces Drivers, Restraints, and Opportunities affect key business dimensions including Growth, Competition, Customer Behavior, Regulation, and Innovation.
| Market Forces ↓ / Impact Areas → | Market Growth Rate | Competitive Landscape | Customer Behavior | Regulatory Influence | Innovation Potential |
|---|---|---|---|---|---|
| Drivers | High impact (e.g., tech adoption, rising demand) | Encourages new entrants and fosters expansion | Increases usage and enhances demand elasticity | Often aligns with progressive policy trends | Fuels R&D initiatives and product development |
| Restraints | Slows growth (e.g., high costs, supply chain issues) | Raises entry barriers and may drive market consolidation | Deters consumption due to friction or low awareness | Introduces compliance hurdles and regulatory risks | Limits innovation appetite and risk tolerance |
| Opportunities | Unlocks new segments or untapped geographies | Creates white space for innovation and M&A | Opens new use cases and shifts consumer preferences | Policy shifts may offer strategic advantages | Sparks disruptive innovation and strategic alliances |
Drivers
- Continuous Monitoring
- Precision Delivery
-
Improved Control : Improved control is a paramount objective within the Global CIS Insulin Market, reflecting the ongoing pursuit of enhanced glycemic management, reduced hypoglycemia risk, and improved quality of life for individuals with diabetes. Continuous Insulin Infusion Systems (CIS) have emerged as a pivotal tool in achieving these goals by offering precise and customizable insulin delivery, real-time glucose monitoring, and proactive management of glycemic fluctuations. By providing continuous subcutaneous insulin infusion and integrating with continuous glucose monitoring (CGM) technology, CIS devices enable patients to maintain tighter glycemic control and minimize glycemic variability compared to conventional insulin regimens. This improved glycemic control translates into reduced hemoglobin A1c (HbA1c) levels, fewer hyperglycemic and hypoglycemic episodes, and better long-term health outcomes for diabetes patients.
One of the key factors driving improved control within the Global CIS Insulin Market is the integration of advanced technologies and smart algorithms into CIS devices, enabling personalized and proactive diabetes management. Hybrid closed-loop systems, also known as artificial pancreas systems, exemplify this innovation by combining insulin pump technology with predictive algorithms and automated insulin adjustment algorithms. These systems continuously monitor glucose levels and adjust insulin delivery in real time based on predictive trends, meal consumption, physical activity, and other physiological parameters, optimizing glycemic control while minimizing the risk of hypoglycemia. Additionally, user-friendly interfaces, smartphone connectivity, and remote monitoring capabilities enhance patient engagement, adherence, and satisfaction with CIS therapy, fostering long-term success in diabetes management.
The continuous evolution and refinement of CIS technology, coupled with ongoing research and development efforts, are driving further improvements in glycemic control and patient outcomes within the Global CIS Insulin Market. Manufacturers are investing in the development of next-generation CIS devices with advanced features such as closed-loop insulin delivery, artificial intelligence algorithms, customizable insulin dosing algorithms, and predictive analytics for glucose forecasting. These innovations aim to address unmet needs in diabetes care, such as nocturnal hypoglycemia prevention, exercise-related glucose management, and personalized insulin dosing optimization. By harnessing the power of technology and innovation, the Global CIS Insulin Market is poised to revolutionize diabetes management, empowering patients to achieve better glycemic control, minimize diabetes-related complications, and improve overall quality of life.
Restraints
- Regulatory Compliance
- Device Complexity
-
Cost Concerns : Cost concerns are significant considerations in the Global CIS (Continuous Subcutaneous Insulin) Market, affecting both healthcare providers and patients. While CIS offers benefits such as improved glycemic control, reduced risk of hypoglycemia, and enhanced quality of life for individuals with diabetes, the initial investment and ongoing expenses associated with insulin pump therapy can be substantial. Healthcare providers must consider the upfront costs of purchasing CIS devices, infusion sets, and insulin reservoirs, as well as the expenses related to training patients and healthcare professionals on device usage and maintenance. Ongoing costs such as consumables, insulin supplies, and device upgrades contribute to the overall cost of CIS therapy, posing financial challenges for healthcare systems and patients alike.
For patients with diabetes, affordability and accessibility of CIS therapy are significant concerns, particularly in regions with limited insurance coverage or out-of-pocket payment models. The high cost of CIS devices and supplies may present barriers to adoption and adherence for individuals with limited financial resources or inadequate insurance coverage. Disparities in access to healthcare services and socioeconomic factors, such as income level and employment status, may exacerbate cost concerns and contribute to inequalities in diabetes management outcomes. Patients may face difficult choices between managing the costs of diabetes care and meeting other essential needs, potentially compromising their health and well-being.
Addressing cost concerns in the Global CIS Insulin Market requires collaborative efforts from stakeholders across the healthcare ecosystem, including manufacturers, policymakers, payers, and advocacy organizations. Manufacturers can explore strategies to reduce the production costs of CIS devices and accessories, streamline supply chains, and optimize manufacturing processes to make CIS therapy more affordable and accessible for patients. Policymakers and payers play a crucial role in developing reimbursement policies, insurance coverage schemes, and patient assistance programs to alleviate financial burdens associated with CIS therapy and ensure equitable access to diabetes care. Healthcare providers can implement cost-effective diabetes management strategies, such as value-based care models, patient education programs, and integrated care pathways, to optimize resource utilization and improve the affordability of CIS therapy for patients with diabetes.
Opportunities
- Patient Empowerment
- Improved Outcomes
-
Integration Solutions : Integration solutions are a pivotal component of the Global CIS Insulin Market, facilitating seamless interoperability between Continuous Insulin Infusion Systems (CIS) and other diabetes management technologies. These solutions enable the integration of CIS devices with complementary technologies such as continuous glucose monitoring (CGM) systems, insulin dose calculators, smartphone apps, and cloud-based platforms, creating an interconnected ecosystem for diabetes care. By integrating CIS devices with CGM systems, patients gain real-time insights into their glucose levels, enabling proactive adjustments to insulin dosing and reducing the risk of hypo- and hyperglycemic events. Moreover, integration solutions can automate insulin delivery algorithms based on CGM data, optimizing glycemic control and minimizing the burden of diabetes management for patients.
Integration solutions also play a crucial role in enhancing patient engagement and empowerment by providing access to actionable insights, personalized recommendations, and remote monitoring capabilities. Through smartphone apps and web-based platforms, patients can track their glucose levels, insulin doses, carbohydrate intake, physical activity, and other relevant metrics in real-time, empowering them to make informed decisions about their diabetes management. Healthcare providers can remotely monitor patients' data, identify trends, and intervene proactively to optimize insulin therapy, address adherence issues, and prevent diabetes-related complications. Integration solutions facilitate communication and data sharing between patients and healthcare providers, enabling collaborative decision-making and personalized care planning to improve diabetes outcomes.
Integration solutions drive innovation and differentiation in the Global CIS Insulin Market by enabling the development of advanced features and functionalities that enhance user experience, treatment efficacy, and device interoperability. Manufacturers leverage integration solutions to incorporate artificial intelligence (AI), machine learning algorithms, predictive analytics, and decision support tools into CIS devices and companion apps, offering personalized insulin dosing recommendations, adaptive insulin delivery algorithms, and predictive alerts for impending hypoglycemia or hyperglycemia events. Integration with electronic health record (EHR) systems, telemedicine platforms, and wearable technologies further expands the utility and accessibility of CIS devices, enabling seamless data exchange, remote consultations, and holistic diabetes management across care settings. As integration solutions continue to evolve and mature, the Global CIS Insulin Market is poised to witness continued growth and innovation, driving improvements in diabetes care and patient outcomes on a global scale.
CIS Insulin Market Competitive Landscape Analysis
CIS Insulin Market is witnessing significant competition, driven by continuous innovation and strategic partnerships among key players. Over 60% of market share is controlled by leading companies, while emerging firms contribute to growth through novel insulin formulations. Collaborative strategies and mergers are accelerating market expansion in the region.
Market Structure and Concentration
The CIS insulin market is moderately concentrated, with top players holding about 55% of the share, while emerging companies capture around 30%. This fosters healthy competition and encourages innovation. Companies leverage strategic collaborations and partnerships to drive growth and expand their presence across the CIS region.
Brand and Channel Strategies
Leading brands employ diverse channel strategies, with more than 40% of sales derived from hospital and pharmacy distribution networks. Strategic collaboration with healthcare providers ensures wider access to insulin products. These strategies help strengthen market position and support steady growth and regional expansion.
Innovation Drivers and Technological Advancements
Technological advancements in insulin delivery systems and drug formulations account for over 60% of market growth. Companies invest in continuous innovation to improve treatment efficacy and patient convenience. Strategic partnerships with research institutions and biotech firms accelerate development, supporting long-term market expansion.
Regional Momentum and Expansion
Russia leads the market with over 40% share, followed by key CIS nations with growing demand for insulin products. Regional growth is driven by increasing diabetes prevalence and expanding healthcare access. Strategic partnerships with local distributors and healthcare providers fuel continued expansion across the CIS region.
Future Outlook
The future outlook for the CIS insulin market is promising, with sustained growth supported by technological advancements and strategic mergers. Over 55% of companies are expected to focus on next-generation insulin formulations. Competitive advantage will rely on innovation, regional expansion, and enhanced collaborations in the healthcare space.
Key players in CIS Insulin Market include:
- Novo Nordisk A/S
- Sanofi S.A.
- Eli Lilly and Company
- Boehringer Ingelheim International GmbH
- Oramed Pharmaceuticals Inc.
- Merck & Co., Inc.
- Bristol-Myers Squibb Company
- Novartis AG
- Biocon Limited
- Takeda Pharmaceuticals
- Dongbao Enterprise (Tonghua Dongbao)
- Wockhardt Ltd.
- Julphar (Gulf Pharmaceutical Industries)
- United Laboratories International Holdings
- Gan & Lee Pharmaceuticals
In this report, the profile of each market player provides following information:
- Market Share Analysis
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Product
- Market Snapshot, By Type
- Market Snapshot, By Application
- Market Snapshot, By Distribution
- Market Snapshot, By Region
- CIS Insulin Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
- Continuous Monitoring
- Precision Delivery
- Improved Control
- Restraints
- Regulatory Compliance
- Device Complexity
- Cost Concerns
- Opportunities
- Patient Empowerment
- Improved Outcomes
- Integration Solutions
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- CIS Insulin Market, By Product, 2021-2031 (USD Million)
- Rapid-Acting Insulin
- Long-Acting Insulin
- Combination Insulin
- Biosimilar
- Others
- CIS Insulin Market, By Type, 2021-2031 (USD Million)
- Human Insulin
- Insulin Analog
- CIS Insulin Market, By Application, 2021-2031 (USD Million)
- Type I Diabetes
- Type II Diabetes
- CIS Insulin Market, By Distribution, 2021-2031 (USD Million)
- Hospitals
- Pharmacies
- Retail & Specialty Pharmacies
- Others
- CIS Insulin Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- CIS Insulin Market, By Product, 2021-2031 (USD Million)
- Competitive Landscape
- Company Profiles
- Novo Nordisk A/S
- Sanofi S.A.
- Eli Lilly and Company
- Boehringer Ingelheim International GmbH
- Oramed Pharmaceuticals Inc.
- Merck & Co., Inc.
- Bristol-Myers Squibb Company
- Novartis AG
- Biocon Limited
- Takeda Pharmaceuticals
- Dongbao Enterprise (Tonghua Dongbao)
- Wockhardt Ltd.
- Julphar (Gulf Pharmaceutical Industries)
- United Laboratories International Holdings
- Gan & Lee Pharmaceuticals
- Company Profiles
- Analyst Views
- Future Outlook of the Market